- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Launch of Cannabis Science and Technology Magazine
Our new sister publication, Cannabis Science and Technology (CST), launched in March 2018. In alliance with the Cannabis Science Conference, this new professional journal and website will focus on educating the legal cannabis industry about the science and technology of analytical testing and quality control, including topics such as
· Sample preparation techniques for analytical testing
· Development of analytical methods for potency testing
· Identifying contaminants such as pesticides, residual solvents, heavy metals, and mycotoxins
· Quality control for cannabis, extraction, and processing
· Laboratory best practices and certification
· Testing standardization
· Regulations related to quality control
The first issue features content ranging from quality assurance, laboratory accreditation, analytical tools to analyze edibles, metals analysis, extraction processes, and more. To read the full issue, please visit www.cannabissciencetech.com/journal/cannabis-science-and-technology-vol-1-no-1 or download the digital edition.
If you would like to submit an article to Cannabis Science and Technology, contact Meg L’Heureux, Editor-in-Chief at Meg.Lheureux@ubm.com.
For subscription information, please visit http://www.cannabissciencetech.com/subscribe
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
